Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by von der Weid, N.
Right arrow Articles by Bianchetti, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by von der Weid, N.
Right arrow Articles by Bianchetti, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrology Dialysis Transplantation, Vol 14, Issue 6 1441-1444, Copyright © 1999 by Oxford University Press

ORIGINAL ARTICLES

Cisplatin therapy in childhood: renal follow up 3 years or more after treatment

N von der Weid, B Erni, C Mamie, H Wagner and M Bianchetti
Department of Pediatrics, Inselspital, CH-2010 Bern, Switzerland; Corresponding author

Background: In childhood, cisplatin is an essential component of solid tumour therapy such as in neuroblastomas, germ cell tumours, bone tumours, liver tumours and brain tumours. The potential nephrotoxicity of cisplatin is widely recognized, but little information is available on permanent sequelae. Methods: Of the 500 children included in the Swiss Pediatric Oncology Group Late Effect Study, a group of 46 patients (27 males and 19 females) aged 5.7-28 years (median 14 years) surviving the above-mentioned solid tumours entered the present study. The patients were disease-free and off antineoplastic medication for at least 3 years. No recent gastrointestinal or urinary disturbances had occurred, and diets as well as appetites were normal. Results: Blood pressure and plasma or urinary calcium and phosphate were similar in 17 patients treated with cisplatin (dose 142-717, median 400 mg/m2), in 19 patients without cisplatin and in 20 control subjects. A tendency (P <0.02) towards increased plasma creatinine (79 (69-89) &mgr;mol/l; median and interquartile range) and low plasma magnesium (0.80 (0.78-0.85) mmol/l) was noted in patients treated with cisplatin as compared with those without cisplatin (68 (58-80) &mgr;mol/l; 0.84 (0.79-0.90) mmol/l). No correlation was noted between the dosage of cisplatin and circulating magnesium or creatinine. Conclusions: The study demonstrates that the permanent renal disturbances ((i) decreased renal function and (ii) hypomagnesaemia) noted after treatment with cisplatin during infancy or childhood are mild. Furthermore, the study does not demonstrate renal sequelae in patients with the same malignancies who had been treated without cisplatin. Key words: children; chronic; cisplatin; kidney failure; magnesium deficiency
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Physiol. Rev.Home page
L.-J. Dai, G. Ritchie, D. Kerstan, H. S. Kang, D. E. C. Cole, and G. A. Quamme
Magnesium Transport in the Renal Distal Convoluted Tubule
Physiol Rev, January 1, 2001; 81(1): 51 - 84.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.